JP2004507531A5 - - Google Patents

Download PDF

Info

Publication number
JP2004507531A5
JP2004507531A5 JP2002523479A JP2002523479A JP2004507531A5 JP 2004507531 A5 JP2004507531 A5 JP 2004507531A5 JP 2002523479 A JP2002523479 A JP 2002523479A JP 2002523479 A JP2002523479 A JP 2002523479A JP 2004507531 A5 JP2004507531 A5 JP 2004507531A5
Authority
JP
Japan
Prior art keywords
carbon atoms
alkyl
compound
compound according
cyclopropyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2002523479A
Other languages
English (en)
Japanese (ja)
Other versions
JP2004507531A (ja
Filing date
Publication date
Priority claimed from US09/651,234 external-priority patent/US6387951B1/en
Priority claimed from US09/651,235 external-priority patent/US6252090B1/en
Priority claimed from US09/651,001 external-priority patent/US6291677B1/en
Priority claimed from US09/651,564 external-priority patent/US6380256B1/en
Priority claimed from US09/651,003 external-priority patent/US6303785B1/en
Priority claimed from US09/651,566 external-priority patent/US6369225B1/en
Priority claimed from US09/651,004 external-priority patent/US6369261B1/en
Application filed filed Critical
Priority claimed from PCT/US2001/025443 external-priority patent/WO2002018361A2/en
Publication of JP2004507531A publication Critical patent/JP2004507531A/ja
Publication of JP2004507531A5 publication Critical patent/JP2004507531A5/ja
Pending legal-status Critical Current

Links

JP2002523479A 2000-08-29 2001-08-14 シトクロムｐ４５０ｒａｉ阻害剤としての活性を有する化合物 Pending JP2004507531A (ja)

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
US09/651,234 US6387951B1 (en) 2000-08-29 2000-08-29 Compounds having activity as inhibitors of cytochrome P450RAI
US09/651,235 US6252090B1 (en) 2000-08-29 2000-08-29 Compounds having activity as inhibitors of cytochrome P450RAI
US09/651,001 US6291677B1 (en) 2000-08-29 2000-08-29 Compounds having activity as inhibitors of cytochrome P450RAI
US09/651,564 US6380256B1 (en) 2000-08-29 2000-08-29 Compounds having activity as inhibitors of cytochrome P450RAI
US09/651,003 US6303785B1 (en) 2000-08-29 2000-08-29 Compounds having activity as inhibitors of cytochrome P450RAI
US09/651,566 US6369225B1 (en) 2000-08-29 2000-08-29 Compounds having activity as inhibitors of cytochrome P450RAI
US09/651,004 US6369261B1 (en) 2000-08-29 2000-08-29 Compounds having activity as inhibitors of cytochrome P450RAI
PCT/US2001/025443 WO2002018361A2 (en) 2000-08-29 2001-08-14 Compounds having activity as inhibitors of cytochrome p450rai

Publications (2)

Publication Number Publication Date
JP2004507531A JP2004507531A (ja) 2004-03-11
JP2004507531A5 true JP2004507531A5 (cg-RX-API-DMAC10.html) 2008-10-02

Family

ID=27569871

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2002523479A Pending JP2004507531A (ja) 2000-08-29 2001-08-14 シトクロムｐ４５０ｒａｉ阻害剤としての活性を有する化合物

Country Status (8)

Country Link
EP (1) EP1366036B1 (cg-RX-API-DMAC10.html)
JP (1) JP2004507531A (cg-RX-API-DMAC10.html)
AT (1) ATE315558T1 (cg-RX-API-DMAC10.html)
AU (2) AU2001286471B2 (cg-RX-API-DMAC10.html)
CA (1) CA2420869A1 (cg-RX-API-DMAC10.html)
DE (1) DE60116642T2 (cg-RX-API-DMAC10.html)
ES (1) ES2256288T3 (cg-RX-API-DMAC10.html)
WO (1) WO2002018361A2 (cg-RX-API-DMAC10.html)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6313107B1 (en) * 2000-08-29 2001-11-06 Allergan Sales, Inc. Methods of providing and using compounds having activity as inhibitors of cytochrome P450RAI
US7482366B2 (en) 2001-12-21 2009-01-27 X-Ceptor Therapeutics, Inc. Modulators of LXR
US7998986B2 (en) 2001-12-21 2011-08-16 Exelixis Patent Company Llc Modulators of LXR
US6740676B2 (en) * 2002-03-19 2004-05-25 Allergan, Inc. 4-[(8-ethynyl, 8-vinyl or 8-ethynyl-methyl)-6-chromanoyl]-benzoic and 2-[4-[(8-ethynyl, 8-vinyl or 8-ethynyl-methyl)-6-chromanoyl]-phenyl]-acetic acid, their esters and salts having cytochrome p450rai inhibitory activity
US7504508B2 (en) 2002-10-04 2009-03-17 Millennium Pharmaceuticals, Inc. PGD2 receptor antagonists for the treatment of inflammatory diseases
PL376156A1 (en) 2002-10-04 2005-12-27 Millennium Pharmaceuticals, Inc. Pgd2 receptor antagonists for the treatment of inflammatory diseases
GB0302094D0 (en) 2003-01-29 2003-02-26 Pharmagene Lab Ltd EP4 receptor antagonists
AU2004268455B2 (en) 2003-08-29 2009-12-17 Ono Pharmaceutical Co., Ltd. Compound capable of binding S1P receptor and pharmaceutical use thereof
GB0324269D0 (en) 2003-10-16 2003-11-19 Pharmagene Lab Ltd EP4 receptor antagonists
US7226951B2 (en) * 2003-12-17 2007-06-05 Allergan, Inc. Compounds having selective cytochrome P450RAI-1 or selective cytochrome P450RAI-2 inhibitory activity and methods of obtaining the same
CA2591399C (en) 2004-12-13 2014-05-20 Ono Pharmaceutical Co., Ltd. Aminocarboxylic acid derivative and medicinal use thereof
CA2589363A1 (en) 2004-12-13 2006-06-22 Eli Lilly And Company Spiro derivatives as lipoxygenase inhibitors
BRPI0608553A2 (pt) 2005-02-24 2010-01-12 Millennium Pharm Inc antagonistas de receptor de pgd2 para o tratamento de doenças inflamatórias
BR112013012836A2 (pt) * 2010-11-24 2019-09-24 Allergan Inc moduladores dos receptores s1p"
JP2014527083A (ja) 2011-09-15 2014-10-09 アリゾナ ボード オブ リージェンツ， ア ボディー コーポレイト オブ ザ ステート オブ アリゾナ， アクティング フォー アンド オン ビハーフ オブ アリゾナ ステート ユニバーシティー 治療用化合物
WO2015109318A2 (en) 2014-01-17 2015-07-23 Arizona Board Of Regents, A Body Corporate Of The State Of Arizona, Acting For And On Behalf Of Arizona State University Therapeutic methods
WO2016055800A2 (en) * 2014-10-10 2016-04-14 High Force Research Limited Fluorescent synthetic retinoids
US10238655B2 (en) 2017-01-23 2019-03-26 Arizona Board Of Regents On Behalf Of Arizona State University Dihydroindene and tetrahydronaphthalene compounds
US10231947B2 (en) 2017-01-23 2019-03-19 Arizona Board Of Regents On Behalf Of Arizona State University Isochroman compounds and methods of use thereof
US10238626B2 (en) 2017-01-23 2019-03-26 Arizona Board Of Regents On Behalf Of Arizona State University Therapeutic compounds

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3475305D1 (en) * 1983-07-05 1988-12-29 Pfizer Carboxylic acid derivatives useful for inhibiting the degradation of cartilage
JPS6323868A (ja) * 1986-07-11 1988-02-01 イー・アイ・デュポン・ドゥ・ヌムール・アンド・カンパニー アンギオテンシン２受容体遮断性イミダゾ−ル
US5089509A (en) * 1988-09-15 1992-02-18 Allergan, Inc. Disubstituted acetylenes bearing heteroaromatic and heterobicyclic groups having retinoid like activity
US5015658A (en) * 1988-06-29 1991-05-14 Allergan, Inc. Thiochroman esters of phenols and terephthallates having retinoid-like activity
US5045551A (en) * 1989-09-19 1991-09-03 Allergan, Inc. Acetylenes disubstituted with a heteroaromatic group and a 2-substituted chromanyl, thiochromanyl or 1,2,3,4-tetrahydroquinolinyl group having retinoid-like activity
US5023341A (en) * 1989-09-19 1991-06-11 Allergan, Inc. Compounds having a disubstituted acetylene moiety and retinoic acid-like biological activity
US5202471A (en) * 1990-02-06 1993-04-13 Allergan, Inc. Alkyl, alkoxy and thioalkoxy substituted diphenyl acetylenes having retinoid like activity
US5134159A (en) * 1991-03-26 1992-07-28 Allergan, Inc. 7-chromanyl esters of phenols and benzoic acids having retinoid-like activity
US5489584A (en) * 1994-12-29 1996-02-06 Allergan, Inc. Acetylenes disubstituted with a 5-amino or substituted 5-amino substituted tetrahydronaphthyl group and with an aryl or heteroaryl group having retinoid-like biological activity
US5498795A (en) * 1994-12-29 1996-03-12 Allergan, Inc. Acetylenes disubstituted with hydroxyaryl and aryl or heteroaryl groups having retinoid-like biological activity
AU698527B2 (en) * 1994-12-29 1998-10-29 Allergan, Inc. Acetylenes disubstituted with a 5 or 8 substituted tetrahydronaphthyl or dihydronaphthyl group and with an aryl or heteroaryl groups having retinoid-like biological activity
US5965606A (en) * 1995-12-29 1999-10-12 Allergan Sales, Inc. Methods of treatment with compounds having RAR.sub.α receptor specific or selective activity
US5739338A (en) * 1996-11-05 1998-04-14 Allergan N-aryl substituted tetrahydroquinolines having retinoid agonist, retinoid antagonist or retinoid inverse agonist type biological activity

Similar Documents

Publication Publication Date Title
JP2004509955A5 (cg-RX-API-DMAC10.html)
JP2005501120A5 (cg-RX-API-DMAC10.html)
HRP20160450T1 (hr) Novi inhibitori reduktaze s-nitrozoglutationa
HUS2000014I1 (hu) Glikopirrolátot és egy béta2 adrenoreceptor agonistát tartalmazó gyógyszerkészítmény
WO2002045703A3 (en) Mixtures or organic compounds for the treatmentof airway diseases
EP2039687A4 (en) THERAPEUTIC OR PROPHYLACTIC AGENT AGAINST MULTIPLE SCLEROSIS
RU2002103603A (ru) Фармацевтические композиции, содержащие ингибитор hmg редуктазы
JP2007514773A5 (cg-RX-API-DMAC10.html)
WO2006018718A3 (en) Triazolopyridinylsulfanyl derivatives as p38 map kinase inhibitors
WO2004096134A3 (en) Substituted 1,4-diazepines and uses thereof
DE60125026D1 (de) Fluorisochinolinderivate, verfahren zu ihrer herstellung und ihre anwendung
JP2002513793A5 (cg-RX-API-DMAC10.html)
SI1622610T1 (sl) 1-(2H-pirazol-3-il)-3-(4-(1-(benzoil)-piperidin-4-ilmetil)-fenil)-urea derivati in sorodne spojine kot inhibitorji p38 kinaze in/ali TNF inhibitorji za zdravljenje vnetij
WO2005016261A3 (en) Aripiprazole and haloperidol pamoate salts
JP2005511547A5 (cg-RX-API-DMAC10.html)
JP2007502265A5 (cg-RX-API-DMAC10.html)
JP2004502732A5 (cg-RX-API-DMAC10.html)
WO2001019814A3 (en) Carboxylic acids and acylsulfonamides, compositions containing such compounds and methods of treatment
RU2006144710A (ru) Новые производные циклопента [b] бензофурана и их применение
JP2006522824A5 (cg-RX-API-DMAC10.html)
JP2003512327A5 (cg-RX-API-DMAC10.html)
MY135954A (en) Crystalline form of (s)-ethoxy-3-4-(2-4-methanesulfonyloxyphenyl ethoxy) phenyl] propanoic acid
WO2005011594A3 (en) Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with a tyrosine kinase inhibitor, delta opioid receptor antagonist, neurokinin receptor antagonist, or vcam inhibitor for treatment of asthma or chronic obstructive pulmonary disease
JP2013510155A5 (cg-RX-API-DMAC10.html)
JP2001510793A5 (cg-RX-API-DMAC10.html)